Sponsored By

The Tel Aviv, Israel-based company uses RF waves to measure glucose in the blood.

MDDI Staff

March 23, 2023

2 Min Read
IMG_2023-3-22-160715.jpg
Image Credit: John Lund via Getty Images

Hagar, the developer of GWave, a non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, announced preliminary data from its clinical study with Professor Ami Navon from the Weizmann Institute of Science for its non invasive glucose monitoring device, GWave.

In contrast to invasive continuous glucose monitors currently available in the market, GWave measures blood glucose as opposed to the interstitial fluid which creates a greater lag time. The accuracy gained by measuring the blood glucose provides both pre-diabetic and diabetic individuals the opportunity to monitor their glucose levels non-invasively, whilst working towards prevention and reduction in overall risk. In addition to its accuracy, the GWave device is a third of the size of a smartphone and contains significantly less radio frequency exposure than the average smartphone.

This current ongoing study demonstrates the significant accuracy of GWave’s technology. Participants were tested multiple times on two separate GWave devices using capillary blood as the benchmark. All results fell within the A Zone on the Clarke Error Grid Analysis (EGA). Blood glucose levels ranged from 70-140. The study will focus on continued data collection on higher blood glucose levels. Hagar said it plans to conduct two additional studies, one at Schneider Children’s Medical Center of Israel and one led by the esteemed Dr. Roy Beck, Founder and Director of the Jaeb Center for Health Research (JCHR) in Tampa, Florida.

Most recently, Hagar said it partnered with a multinational chip manufacturer specializing in RF to mass-produce its chips. The partnership enables Hagar to deliver a complete 360-degree product. By bringing in the Taiwanese-based manufacturer, Hagar’s technology brings a significant breakthrough when it comes to the reproducibility of the device.

This year proves to be an exciting time for Hagar’s leadership team. The company welcomes Dr. Moshe Phillip, Director of the Institute of Endocrinology at Schneider Children’s Hospital and co-chairman of the International Conference for Advanced Technologies and Treatments of Diabetes (ATTD), as a medical advisor. Dr. Phillip joins Hagar’s advisory board with some of the industry’s most renowned experts, such as Dr. Alexander Fleming and Dr. Irl Hirsch, who recently was awarded the President’s Innovation Award at ATTD.

This clinical trial is part of the ongoing efforts of Hagar to demonstrate how effective its technology is in helping patients manage their health and reduce the risks of long-term complications. In its final form, GWave’s technology will be integrated into a smartwatch, adding to its accessibility and affordability for patients worldwide.

The company is completing a Series C funding round and the capital will be allocated towards the upcoming studies planned for Israel and the US.

 

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like